Paeds SAQs · genetics-dysmorphology-and-metabolism
Genomic testing, variant interpretation, and counselling — formative SAQs
Formative SAQs on choosing the right genomic test, applying the ACMG/AMP five-tier variant classification framework, managing variants of uncertain significance and secondary findings, and delivering pre- and post-test genetic counselling to families.
On this page
Study tools
Target exams
SAQ 1 (10 marks)
A four-year-old boy is referred for global developmental delay, mild dysmorphic features, and a paternal family history of learning difficulty. His chromosomal microarray returned normal. The paediatrician has now ordered trio exome sequencing. The parents ask what this test involves and what it might find. [2] [9]
a) Explain why a normal chromosomal microarray does not exclude a genetic diagnosis, and justify the escalation to exome sequencing. (3 marks) [2] [9]
b) Describe the ACMG/AMP five-tier variant classification framework, naming each tier and giving the approximate probability range for a variant of uncertain significance. (3 marks) [1]
c) Outline the domains you would cover in the pre-test counselling conversation, including the option of secondary findings and the management of a potential VUS. (2 marks) [5] [9]
d) Explain why trio sequencing (proband plus both parents) is preferred over proband-only sequencing, naming two advantages. (2 marks) [9]
References4ShowHide
- [1]Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med, 2015.PMID 25741868
- [2]Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet, 2010.PMID 20466091
- [5]Miller DT, Lee K, Chung WK, et al. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement. Genet Med, 2021.PMID 34012068
- [9]Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the ACMG. Genet Med, 2021.PMID 34211152